Delineating the mechanism of Alzheimer's disease Aβ peptide neurotoxicity

Neurochemical Research

Volumn 33, Issue 3, 2008, Pages 526-532

  Cappai, Roberto ^a,b,c   Barnham, Kevin J ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Aggregation; Alzheimer's disease; Amyloid; Copper; Neurotoxicity; Reactive oxygen species

Indexed keywords

AMYLOID BETA PROTEIN; CHELATING AGENT; CLIOQUINOL; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; DP 109; JKL 169; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE; TRICYCLODECAN 9 YL XANTHOGENATE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL CULTURE; CELL FUNCTION; CLINICAL TRIAL; COPPER DEFICIENCY; HUMAN; NERVE CELL; NEUROTOXICITY; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; WILSON DISEASE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; HUMANS; METALS; NEUROTOXICITY SYNDROMES; OXIDATION-REDUCTION;

EID: 38949205552     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11064-007-9469-8     Document Type: Review

References (103)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356
2. Masters CL, Cappai R, Barnham KJ et al (2006) Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 97:1700-1725
3. Kang J, Lemaire H, Unterbeck A et al (1987) The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325:733-736
4. Haass C, Schlossmacher MG, Hung AY et al (1992) Amyloid β-peptide is produced by cultured cells during normal metabolism. Nature 359:322-325
5. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32:4693-4697
6. Liao MQ, Tzeng YJ, Chang LY et al (2007) The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. FEBS Lett 581:1161-1165
7. Yankner BA, Duffy LK, Kirschner DA (1990) Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science 250:279-282
8. Pike CJ, Burdick D, Walencewicz AJ et al (1993) Neurodegeneration induced by β-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13:1676-1687
9. Pike CJ, Walencewicz AJ, Glabe CG et al (1991) In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 563:311-314
10. Pike CL, Walencewicz AJ, Glabe CG et al (1991) Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur J Pharmacol 207:367-368
11. Walsh DM, Klyubin I, Fadeeva JV et al (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539
12. Lambert MP, Barlow AK, Chromy BA et al (1998) Diffusible, nonfibrillar ligands derived from Ab1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453
13. Smith DP, Ciccotosto GD, Tew DJ et al (2007) Concentration dependent Cu(2+) induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry 46:2881-2891
14. Barghorn S, Nimmrich V, Striebinger A et al (2005) Globular amyloid beta-peptide oligomer-a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem 95:834-847
15. Lesne S, Koh MT, Kotilinek L et al (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357
16. McLean CA, Cherny RA, Fraser FW et al (1999) Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46:860-866
17. Lue LF, Kuo YM, Roher AE et al (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155:853-862
18. Wang J, Dickson DW, Trojanowski JQ et al (1999) The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158:328-337
19. Naslund J, Haroutunian V, Mohs R et al (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571-1577
20. Yun SH, Gamkrelidze G, Stine WB et al (2006) Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus. Neurosci Lett 403:162-165
21. Klyubin I, Walsh DM, Cullen WK et al (2004) Soluble Arctic amyloid beta protein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci 19:2839-2846
22. Klyubin I, Walsh DM, Lemere CA et al (2005) Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556-561
23. Trommer BL, Shah C, Yun SH et al (2005) ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol Dis 18:75-82
24. Wang HW, Pasternak JF, Kuo H et al (2002) Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res 924:133-140
25. Chen QS, Kagan BL, Hirakura Y et al (2000) Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J Neurosci Res 60:65-72
26. Cleary JP, Walsh DM, Hofmeister JJ et al (2005) Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8:79-84
27. Small DH, Mok SS, Bornstein JC (2001) Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci 2:595-598
28. Puzzo D, Palmeri A, Arancio O (2006) Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. Rev Neurosci 17:497-523
29. Wang Q, Walsh DM, Rowan MJ et al (2004) Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 24:3370-3378
30. Minogue AM, Schmid AW, Fogarty MP et al (2003) Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus: a role for interleukin-1beta? J Biol Chem 278:27971-27980
31. Chong YH, Shin YJ, Lee EO et al (2006) ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem 281:20315-20325
32. Chin J, Palop JJ, Yu GQ et al (2004) Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24:4692-4697
33. Braithwaite SP, Paul S, Nairn AC et al (2006) Synaptic plasticity: one STEP at a time. Trends Neurosci 29:452-458
34. Snyder EM, Nong Y, Almeida CG et al (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051-1058
35. Rapoport M, Dawson HN, Binder LI et al (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci USA 99:6364-6369
36. Sengupta A, Novak M, Grundke-Iqbal I et al (2006) Regulation of phosphorylation of tau by cyclin-dependent kinase 5 and glycogen synthase kinase-3 at substrate level. FEBS Lett 580:5925-5933
37. Lewis J, Dickson DW, Lin WL et al (2001) Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491
38. Gotz J, Chen F, van Dorpe J et al (2001) Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science 293:1491-1495
39. Roberson ED, Scearce-Levie K, Palop JJ et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316:750-754
40. Ambroggio EE, Kim DH, Separovic F et al (2005) Surface behavior and lipid interaction of Alzheimer {beta}-amyloid peptide 1-42:a membrane-disrupting peptide. Biophys J 88:2706-2713
41. Bhatia R, Lin H, Lal R (2000) Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J 14:1233-1243
42. Lau TL, Ambroggio EE, Tew DJ et al (2006) Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol 356:759-770
43. Holscher C (1998) Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 5:129-141
44. Lin H, Bhatia R, Lal R (2001) Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. FASEB J 15:2433-2444
45. Kourie JI, Henry CL, Farrelly P (2001) Diversity of amyloid beta protein fragment [1-40]-formed channels. Cell Mol Neurobiol 21:255-284
46. Demuro A, Mina E, Kayed R et al (2005) Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 280:17294-17300
47. Kayed R, Head E, Thompson JL et al (2003) Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300:486-489
48. Kourie JI, Culverson AL, Farrelly PV et al (2002) Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis. Cell Biochem Biophys 36:191-207
49. Verdier Y, Zarandi M, Penke B (2004) Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci 10:229-248
50. Yan SD, Chen X, Fu J et al (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691
51. Arancio O, Zhang HP, Chen X et al (2004) RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. EMBO J 23:4096-4105
52. Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489-1499
53. Deane R, Wu Z, Sagare A et al (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333-344
54. De Felice FG, Velasco PT, Lambert MP et al (2007) Abeta oligomers induce neuronal oxidative stress through an N-methyl-d-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601
55. Sabo S, Lambert MP, Kessey K et al (1995) Interaction of beta-amyloid peptides with integrins in a human nerve cell line. Neurosci Lett 184:25-28
56. Bi X, Gall CM, Zhou J et al (2002) Uptake and pathogenic effects of amyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience 112:827-840
57. Coulson EJ (2006) Does the p75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? J Neurochem 98:654-660
58. Zhang Y, Hong Y, Bounhar Y et al (2003) p75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci 23:7385-7394
59. Perini G, Della-Bianca V, Politi V et al (2002) Role of p75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med 195:907-918
60. Crouch PJ, Blake R, Duce JA et al (2005) Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 25:672-679
61. Devi L, Prabhu BM, Galati DF et al (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 26:9057-9068
62. Manczak M, Anekonda TS, Henson E et al (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15:1437-1449
63. Caspersen C, Wang N, Yao J et al (2005) Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19:2040-2041
64. Lustbader JW, Cirilli M, Lin C et al (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304:448-452
65. Takuma K, Yao J, Huang J et al (2005) ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19:597-598
66. White AR, Guirguis R, Brazier MW et al (2001) Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons. Neurobiol Dis 8:299-316
67. Ivins KJ, Bui ET, Cotman CW (1998) Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol Dis 5:365-378
68. Nakagawa T, Zhu H, Morishima N et al (2000) Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403:98-103
69. Casas C, Sergeant N, Itier JM et al (2004) Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol 165:1289-1300
70. Gomez-Ramos P, Asuncion Moran M (2007) Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. J Alzheimers Dis 11:53-59
71. Wegiel J, Kuchna I, Nowicki K et al (2007) Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol (Berl) 113:389-402
72. Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 545:39-50
73. Behl C, Davis JB, Lesley R et al (1994) Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827
74. Cuajungco MP, Goldstein LE, Nunomura A et al (2000) Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Abeta by zinc. J Biol Chem 275:19439-19442
75. Huang X, Atwood CS, Hartshorn MA et al (1999) The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal reduction. Biochemistry 38:7609-7616
76. Huang X, Cuajungco MP, Atwood CS et al (1999) Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274:37111-37116
77. Barnham KJ, Ciccotosto GD, Tickler AK et al (2003) Neurotoxic, redox-competent Alzheimer's beta-amyloid is released from lipid membrane by methionine oxidation. J Biol Chem 278:42959-42965
78. Ciccotosto GD, Tew D, Curtain CC et al (2004) Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem 279:42528-42534
79. Ali FE, Separovic F, Barrow CJ et al (2005) Methionine regulates copper/hydrogen peroxide oxidation products of Abeta. J Pept Sci 11:353-360
80. Schiewe AJ, Margol L, Soreghan BA et al (2004) Rapid characterization of amyloid-beta side-chain oxidation by tandem mass spectrometry and the scoring algorithm for spectral analysis. Pharm Res 21:1094-1102
81. Curtain CC, Ali F, Volitakis I et al (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276:20466-20473
82. Butterfield DA, Griffin S, Munch G et al (2002) Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis 4:193-201
83. Varadarajan S, Kanski J, Aksenova M et al (2001) Different mechanisms of oxidative stress and neurotoxicity for Alzheimer's A beta(1-42) and A beta(25-35). J Am Chem Soc 123:5625-5631
84. Pogocki D, Schoneich C (2002) Redox properties of Met(35) in neurotoxic beta-amyloid peptide. A molecular modeling study. Chem Res Toxicol 15:408-418
85. Naslund J, Schierhorn A, Hellman U et al (1994) Relative abundance of Alzheimer Abeta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A 91:8378-8382
86. Kuo YM, Kokjohn TA, Beach TG et al (2001) Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains. J Biol Chem 276:12991-12998
87. Dong J, Atwood CS, Anderson VE et al (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42:2768-2773
88. Chen K, Kazachkov M, Yu PH (2007) Effect of aldehydes derived from oxidative deamination and oxidative stress on beta-amyloid aggregation; pathological implications to Alzheimer's disease. J Neural Transm 114:835-839
89. Ali FE, Barnham KJ, Barrow CJ et al (2004) Metal catalyzed oxidation of tyrosine residues by different oxidation systems of copper/hydrogen peroxide. J Inorg Biochem 98:173-184
90. Metodiewa D (1998) Molecular mechanisms of cellular injury produced by neurotoxic amino acids that generate reactive oxygen species. Amino Acids 14:181-187
91. Leeuwenburgh C, Hansen PA, Holloszy JO et al (1999) Hydroxyl radical generation during exercise increases mitochondrial protein oxidation and levels of urinary dityrosine. Free Radic Biol Med 27:186-192
92. Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 51:1562-1566
93. Atwood CS, Perry G, Zeng H et al (2004) Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry 43:560-568
94. 2. J Biol Chem 277:40302-40308
95. Barnham KJ, Haeffner F, Ciccotosto GD et al (2004) Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J 18:1427-1429
96. Roher A, Wolfe D, Palutke M et al (1986) Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci USA 83:2662-2666
97. Moret V, Laras Y, Pietrancosta N et al (2006) 1,1′-Xylyl bis-1,4,8,11-tetraaza cyclotetradecane: a new potential copper chelator agent for neuroprotection in Alzheimer's disease. Its comparative effects with clioquinol on rat brain copper distribution. Bioorg Med Chem Lett 16:3298-3301
98. Lee JY, Friedman JE, Angel I et al (2004) The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 25:1315-1321
99. Cherny RA, Atwood CS, Xilinas ME et al (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30:665-676
100. Perluigi M, Joshi G, Sultana R et al (2006) In vivo protection by the xanthate tricyclodecan-9-yl-xanthogenate against amyloid beta-peptide (1-42)-induced oxidative stress. Neuroscience 138:1161-1170
101. Ritchie CW, Bush AI, Mackinnon A et al (2003) Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60:1685-1691
102. White AR, Du T, Laughton KM et al (2006) Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 281:17670-17680
103. Crouch PJ, Barnham KJ, Bush AI et al (2006) Therapeutic treatments for Alzheimer's disease based on metal bioavailability. Drug News Perspect 19:469-474